日前，大冢制药旗下第三代酪氨酸激酶抑制剂——英可欣®(通用名：泊那替尼片)在京东健康全网首 发，为慢性髓性白血病(CML)和费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)患者带来了新的治疗选 择。京东健康将依托自身全渠道供应链和全场景医疗健康服务能力，全面提升这款新药的可及性，让更 多患者从中获益。 英可欣®(通用名：泊那替尼片)的上市，进一步推动了我国血液肿瘤治疗领域的进步，为白血病患者特 别是耐药性和难治性患者带来新的治疗曙光。此次在京东健康首发后，患者能够便捷地购买到这款药 品。京东健康将充分发挥冷链物流优势，确保药品在全程恒温无断链的条件下安全送达患者手中。此 外，京东健康还与大冢制药共同开展疾病教育和患者服务项目，通过科普文章、专家视频等内容，提升 公众对白血病等血液肿瘤的健康素养。 京东健康相关负责人表示，英可欣®的全网首发，有望帮助更多白血病患者提高生活质量。京东健康也 将与大冢制药等合作伙伴继续深化合作，帮助更多患者完成高质量的健康管理，享受更加美好的生活。 在临床试验中，英可欣®展现了卓越的疗效和可控的安全性。例如，在OPTIC试验中，接受泊那替尼治 疗的T315I突变型患者在48个月内 ...

Group 1 - Novo Nordisk and JD Health signed a strategic cooperation agreement on April 21, marking a new phase in their collaboration in diabetes and weight management [2] - Approximately 140 million adults in China suffer from diabetes, and around 180 million adults are obese, with rising prevalence rates [2] - The partnership aims to create a public awareness zone for obesity and facilitate one-stop diabetes treatment, enhancing the digital transformation of chronic disease management [2] Group 2 - The collaboration will establish a multi-party dialogue platform to improve accessibility and convenience of quality healthcare services [3] - Utilizing medical big data analysis and AI-assisted diagnosis systems, the partnership aims to develop a comprehensive smart healthcare solution covering the entire cycle from prevention to management [3]

活动现场，许多健康养老好物也与老人们见面。鱼跃电动轮椅轻便灵活，三诺电子血压仪伸手即测，科 大讯飞助听器、迈德斯特电动护理床、医仑特折叠洗澡椅等适老健康产品，让老年人获得便捷舒适的产 品体验。同时，老金磨方黑芝麻丸、银善存多维元素片等健康产品也让老年人有了更多选择。此外，京 东健康的皮肤检测、春季流感检测、护士到家中医按摩调理服务等项目，也被更多活动参与者所了解。 随着我国老龄化进程的加速，银发经济正成为社会关注的焦点。为了更好地服务老年群体，倡导健康养 老的生活方式，4月15日，京东健康在北京陶然亭公园举办了一场别开生面的"老友迎春会"。此次活动 不仅为老年人提供了一个集健康服务、娱乐互动和社交于一体的场合，更是京东健康在推动健康养老产 业高质量发展方面的一次积极探索。 "老友迎春会"精彩纷呈 活动被"点赞" 活动当天，陶然亭公园洋溢着活力与温暖。活动现场设置了多个板块，将健康服务、互动游戏、文艺表 演和养老产品体验有机融合，为老年人带来一场丰富多彩的春日盛会。 在健康服务方面，由三甲医院医生、心理咨询师、京东健康全职营养师、京东护士到家服务团队、之业 堂推拿正骨医师等组成的京东健康专家团，为老年人提供免费 ...

近日，南京正大天晴旗下希诺彤®(通用名：罗沙司他胶囊)与晴万瑞®(通用名：瑞戈非尼)在京东健康全 网首发。这两款重磅新药的上线，将为慢性肾脏病贫血患者及肿瘤患者提供全新的治疗选择。京东健康 将充分发挥其全渠道供应链和全场景医疗健康服务能力，全面提升药品可及性。 当前，慢性肾脏病已经成为中国重要的公共健康问题。贫血是慢性肾脏病患者最常见的并发症之一，肾 性贫血可加速慢性肾脏病进展，增加透析频率、住院率，严重影响生活质量和疾病预后。而在肿瘤治疗 领域，肝癌、肠癌等恶性肿瘤发病率居高不下，晚期患者治疗选择有限，亟需更多创新药物突破治疗瓶 颈。希诺彤®和晴万瑞®的上市，正是针对这些未满足的临床需求，为患者带来新的用药方案。 希诺彤®(罗沙司他胶囊)于2024年12月17日获批上市，适用于慢性肾脏病引起的贫血，涵盖透析和非透 析患者。罗沙司他是一种小分子低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)类治疗肾性贫血的药物， 具有全新作用机制，与现有常规治疗药物相比，可口服给药，在提高铁利用率、无需静脉补铁等方面具 有临床优势。作为国产罗沙司他，希诺彤®通过了严格的质量和疗效一致性评价，确保了与原研药相当 的疗效和安全性 ...

Core Viewpoint - JD Health collaborates with the Civil Aviation Administration of China to enhance smart healthcare and patient services, aiming to improve hospital operational efficiency and patient experience [1][2]. Group 1: Collaboration Details - The partnership focuses on multiple areas including smart healthcare, supply chain services, and patient services [1]. - JD Health will leverage its strengths in pharmaceutical supply chain, medical big data, and artificial intelligence to provide comprehensive technical support to the Civil Aviation General Hospital [1]. - The collaboration aims to create an AI-based patient service system, utilizing JD Health's large model product, JD Zhuoyi (JOY DOC), to offer solutions like intelligent triage and pre-appointment registration [1]. Group 2: Service Innovations - The initiative promotes a new model of healthcare that combines online and offline services, enhancing convenience for patients [2]. - JD Health will provide online platforms, technical services, and operational support to the Civil Aviation General Hospital, including home nursing services such as intravenous blood collection and post-operative care [1][2]. - The collaboration will also explore the integration of JD Logistics' supply chain capabilities to offer comprehensive pharmaceutical logistics services, ensuring efficient access to necessary medications and materials [2]. Group 3: Future Directions - Both parties plan to deepen their cooperation and explore more innovative models and services to provide convenient, efficient, and high-quality healthcare services [2].

Core Insights - The 2025 Wuzhen Health Conference, featuring a special session by JD Health, focused on the theme of "Unlocking New Growth Curves through Digital Transformation" in the pharmaceutical and health industry [1] - JD Health is leveraging innovative practices and comprehensive growth strategies to invigorate the pharmaceutical health sector amid a dual-driven transformation by policy and market forces [1] Industry Overview - The pharmaceutical industry is undergoing significant changes driven by both policy and market dynamics, with the normalization of national drug procurement accelerating the outflow of prescriptions [1] - The opening of online medical insurance payment policies is expected to release a market potential worth trillions, while the awakening of user health awareness is creating diverse demands [1] Company Strategy - JD Health, as a leading pharmaceutical retail channel, is building an ecological closed loop through four capabilities: "omni-channel marketing, full-scenario coverage, infinite shelf, and AI-driven" [2] - The company has achieved a 45% extension in the chronic disease medication cycle (DOT) and has successfully launched multiple popular products through its "infinite shelf" model [2] Marketing and User Engagement - JD Health has broken down traffic barriers by achieving efficient collaboration between online and offline channels, providing brands with precise user reach and effective traffic conversion [2] - The company utilizes the Jingzhun Tong platform to offer brands controllable advertising marketing tools, aiding in user engagement and brand sales growth [2] Service Capabilities - JD Health has established a service closed loop encompassing "medicine + testing + diagnosis + drugs" through its internet hospital platform and home testing services [3] - The company plans to expand its capabilities in niche areas such as traditional Chinese medicine and DTP pharmacies, aiming to create an integrated online and offline super pharmacy ecosystem [3] Future Outlook - The special session at the 2025 Wuzhen Health Conference showcased JD Health's innovative practices and provided valuable insights for the future development of the pharmaceutical health industry [3] - Through digital upgrades, user experience reconstruction, and comprehensive growth strategies, JD Health is collaborating with industry partners to pioneer a new future in the pharmaceutical health sector [3]

Core Insights - JD Health and United Imaging's subsidiary, United Imaging Microelectronics, have formed a strategic partnership to promote innovative medical technology products, particularly focusing on hearing aids for the hearing-impaired population [1][2] Group 1: Strategic Partnership - The partnership was announced at the 91st China International Medical Equipment Fair (CMEF) [1] - JD Health will exclusively launch United Imaging's new hearing aid series, uOrigin u16, in 2025, along with the u12 Lite model [1][2] - Both companies aim to leverage their strengths to explore innovative models in the hearing health sector [2][3] Group 2: Product Features - The uOrigin u16 hearing aid features 64 signal processing channels and 16 software adjustable channels, tailored for Chinese language characteristics [2] - The product utilizes AI technology for enhanced performance in noise reduction, battery life, and customization [2] - United Imaging also introduced a remote professional fitting service during the CMEF, providing personalized support for hearing rehabilitation [2] Group 3: Market Context - The hearing aid market is experiencing rapid growth due to an aging population and increasing demand for hearing health solutions [2] - JD Health is committed to utilizing internet technology to provide comprehensive medical health solutions [2] - United Imaging has a strong background in high-end medical equipment and AI, which supports the development of hearing aids suitable for Chinese users [2][3]

Core Insights - JD Health and United Imaging's subsidiary, United Imaging Microelectronics, have formed a strategic partnership to promote innovative medical technology products, specifically focusing on hearing solutions for the hearing-impaired population [1][2] Group 1: Strategic Partnership - The partnership was formalized at the 91st China International Medical Equipment Fair (CMEF) with the exclusive launch of United Imaging's new hearing aid series, uOrigin u16, on JD Health [1] - The collaboration aims to leverage JD Health's platform advantages and United Imaging's technological expertise to explore innovative models in the hearing health sector [2][3] Group 2: Product Features - The uOrigin u16 hearing aid features 64 signal processing channels and 16 software-adjustable channels, tailored for Chinese language characteristics to enhance listening clarity and comfort [2] - United Imaging also introduced the uOrigin u12 Lite hearing aid and a remote professional fitting service during the CMEF, providing comprehensive support for hearing rehabilitation [2] Group 3: Market Context - The hearing aid market is experiencing rapid growth due to increasing demand driven by an aging population and heightened awareness of hearing health [2] - JD Health is actively exploring internet technology to provide one-stop medical health solutions, emphasizing the importance of the hearing aid business's rapid development [3]

Core Viewpoint - The article highlights the importance of comprehensive management for constipation and digestive system diseases, emphasizing the role of JD Health in providing accessible and professional health services for patients [1][2][4]. Group 1: Disease Prevalence and Impact - Constipation affects 4% to 6% of adults in China, with the prevalence increasing with age, reaching up to 22% in individuals over 60 years old [2]. - Long-term constipation can lead to serious health issues, including abdominal pain, anal diseases, and cardiovascular problems [2]. Group 2: Comprehensive Health Services - JD Health advocates for a full-cycle management approach for constipation, offering services from prevention and diagnosis to treatment and rehabilitation [2]. - The platform provides extensive educational content on symptoms, causes, prevention, and treatment of digestive system diseases, presented in an easy-to-understand format [2]. Group 3: Diagnostic and Treatment Support - JD Health integrates online and offline resources to facilitate convenient online consultations with top digestive specialists from renowned medical institutions [2]. - The company offers a wide range of medications and personalized medication guidance from professional pharmacists, ensuring safe and effective treatment [3]. Group 4: Long-term Health Management - JD Health employs big data analysis to provide personalized health assessments and management recommendations, including dietary adjustments and exercise plans [3]. - The company collaborates with offline pharmacies and medical institutions to create a comprehensive healthcare network, enhancing service accessibility and efficiency [3]. Group 5: Future Directions - JD Health aims to continue innovating service models to provide more professional, convenient, and efficient health services for constipation patients, while promoting standardized diagnosis and management of digestive system diseases [4].

Core Viewpoint - JD Health is leveraging AI to enhance medical health services, focusing on high-quality development through AI-driven solutions in health management and patient care [1][2]. Group 1: AI in Healthcare - AI is recognized as a new production factor that should address deep-rooted issues across various industries, particularly in healthcare [2]. - JD Health's "Jingyi Qianxun" medical model has been fully open-sourced, making it the first vertical model in the domestic healthcare sector to do so, which will lower the development barriers for medical AI applications [2][3]. - The AI diagnosis assistant 2.0 boasts a triage accuracy rate of 99.5%, with a 120% increase in electronic medical record writing efficiency and over 90% problem-solving rate [3]. Group 2: AI Products and Services - JD Health has launched several AI-driven services, including the intelligent health assistant "Kangkang" and the AI psychological companion "Therapeutic Little Universe," creating an online medical service ecosystem [3]. - The AI doctor digital entity is designed to provide 24/7 responses to patient inquiries, enhancing the efficiency of medical services [3]. Group 3: Data Security and Privacy - The company emphasizes that AI models learn from de-identified "knowledge data" rather than clinical data, addressing data security and privacy concerns [3]. - Patients are informed about the use of their data, allowing them to choose between protecting or sharing their information [3]. Group 4: Future Directions - JD Health aims to continuously explore the potential of AI in healthcare, focusing on technological innovation to build a safer, more efficient, and convenient medical service system [4].